AIM ImmunoTech Inc. (AIM)

Price$0.52

Value ScoreC

Growth ScoreD

Momentum ScoreF

Favorite Metrics

Price vs S&P 500 (26W)-72.84%

Price vs S&P 500 (4W)52.66%

VGM Score31.05

Market Capitalization$7.51M

All Metrics

Book Value / Share (Quarterly)$0.26

P/TBV (Annual)2.71x

Revenue Growth (3Y)-14.54%

Cash Flow / Share (Quarterly)$-1.42

Price vs S&P 500 (YTD)-61.27%

Gross Margin (TTM)-29.79%

Net Profit Margin (TTM)-14123.40%

EPS (TTM)$-7.39

10-Day Avg Trading Volume105.10M

EPS Excl Extra (TTM)$-7.39

Revenue Growth (5Y)-11.60%

EPS (Annual)$-8.62

ROI (Annual)-283.00%

Gross Margin (Annual)-45.45%

Net Profit Margin (5Y Avg)-13669.23%

Cash / Share (Quarterly)$0.71

Revenue Growth QoQ (YoY)37.50%

ROA (Last FY)-241.40%

Revenue Growth TTM (YoY)-35.62%

EBITD / Share (TTM)$-4.06

ROE (5Y Avg)-92.13%

Operating Margin (TTM)-10926.60%

Cash Flow / Share (Annual)$-3.69

P/B Ratio3.54x

P/B Ratio (Quarterly)2.24x

Net Income / Employee (Annual)$-734,600

EV / Revenue (TTM)62.87x

Net Interest Coverage (TTM)-6.50x

ROA (TTM)-221.36%

EV / EBITDA (TTM)0.45x

EPS Incl Extra (Annual)$-8.62

Current Ratio (Annual)0.53x

Quick Ratio (Quarterly)0.96x

3-Month Avg Trading Volume20.66M

52-Week Price Return-92.40%

Revenue / Employee (TTM)$4,900

Tangible BV / Share (Quarterly)$0.06

P/S Ratio (Annual)85.36x

Asset Turnover (Annual)0.02x

52-Week High$19.74

Operating Margin (5Y Avg)-14153.95%

EPS Excl Extra (Annual)$-8.62

CapEx CAGR (5Y)-8.67%

Tangible BV CAGR (5Y)13.20%

26-Week Price Return-64.91%

Quick Ratio (Annual)0.49x

13-Week Price Return-19.41%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)1.01x

Enterprise Value$5.91M

Revenue / Share Growth (5Y)60.55%

Asset Turnover (TTM)0.02x

Book Value / Share Growth (5Y)34.84%

Revenue / Employee (Annual)$4,600

Inventory Turnover (Annual)1.67x

Pretax Margin (Annual)-15861.36%

Cash / Share (Annual)$0.99

3-Month Return Std Dev352.50%

Gross Margin (5Y Avg)-62.82%

Net Income / Employee (TTM)$-698,700

ROE (Last FY)-283.00%

Net Interest Coverage (Annual)-4.16x

EPS Basic Excl Extra (Annual)$-8.62

Receivables Turnover (TTM)12.18x

Total Debt / Equity (Quarterly)1.98x

EPS Incl Extra (TTM)$-7.39

Receivables Turnover (Annual)0.14x

ROI (TTM)-47.69%

P/S Ratio (TTM)79.91x

Pretax Margin (5Y Avg)-13669.23%

Revenue / Share (Annual)$0.05

Tangible BV / Share (Annual)$16.12

Price vs S&P 500 (52W)-116.77%

Year-to-Date Return-53.11%

5-Day Price Return-42.60%

EPS Normalized (Annual)$-8.62

ROA (5Y Avg)-134.65%

Net Profit Margin (Annual)-15861.36%

Month-to-Date Return26.48%

Cash Flow / Share (TTM)$-0.42

EBITD / Share (Annual)$-7.18

Operating Margin (Annual)-13254.55%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-87.54%

LT Debt / Equity (Quarterly)0.10x

EPS Basic Excl Extra (TTM)$-7.39

P/TBV (Quarterly)10.29x

P/B Ratio (Annual)2.10x

Inventory Turnover (TTM)1.67x

Pretax Margin (TTM)-14123.40%

Book Value / Share (Annual)$20.82

Price vs S&P 500 (13W)-27.66%

Beta1.09x

Revenue / Share (TTM)$0.02

ROE (TTM)-142.26%

52-Week Low$0.21

vGradeC

gGradeD

mGradeF

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.57est. -0.37

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.00

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
AIMAIM ImmunoTech Inc.	C	D	F	$0.52
AMGNAmgen Inc	C	C	C	$349.58
GILDGilead Sciences Inc	C	B	C	$129.16
ARGXargenx SE American Depositary Shares	D	A	B	$891.32
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$149.23
BIIBBiogen Inc. Common Stock	B	D	B	$195.34
BNTXBioNTech SE American Depositary Share	C	C	D	$88.08
MRNAModerna, Inc. Common Stock	C	B	B	$47.44
NBIXNeurocrine Biosciences Inc	C	B	B	$163.88
EXELExelixis Inc	C	B	B	$52.70
KRYSKrystal Biotech, Inc. Common Stock	D	B	A	$301.00

About

AIM ImmunoTech is an immunotherapy company developing treatments for cancer, viral infections, and immune disorders. Its lead asset, Ampligen (rintatolimod), a novel double-stranded RNA therapeutic, is approved for commercial sale in Argentina for severe chronic fatigue syndrome. The company also markets Alferon N Injection (Interferon alfa).